Simultaneous runs of the Bayer VERSANT HIV-1 version 3.0 and HCV bDNA version 3.0 quantitative assays on the System 340 platform provide reliable quantitation and improved work flow

Journal of Clinical Microbiology

Volumn 42, Issue 7, 2004, Pages 3120-3127

  Elbeik, Tarek ^a,b   Markowitz, Norman ^d   Nassos, Patricia ^a,b   Kumar, Uday ^d   Beringer, Scott ^c   Haller, Barbara ^a,b   Ng, Valerie ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

^c Professional Habitat Design   (United States)

^d Henry Ford Health System Division of Infectious Diseases   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BRANCHED DNA SIGNAL AMPLIFICATION ASSAY; CENTRIFUGATION; CONTROLLED STUDY; DIAGNOSTIC KIT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYBRIDIZATION; INTERMETHOD COMPARISON; LYSIS; MICROTITER PLATE ASSAY; MIXED INFECTION; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROCESSING; QUANTITATIVE ASSAY; SAMPLE; TECHNIQUE; VIRUS DETECTION; VIRUS LOAD; VIRUS LYSIS; VIRUS TITRATION; WORK FLOW;

DNA, VIRAL; HEPACIVIRUS; HIV-1; HUMANS; REPRODUCIBILITY OF RESULTS; TIME FACTORS; VIRAL LOAD;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 3142702816     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.42.7.3120-3127.2004     Document Type: Article

References (14)

1. Anastassopoulou, C. G., G. Touloumi, A. Katsoulidou, H. Hatzitheodorou, M. Pappa, D. Paraskevis, M. Lazanas, P. Gargalianos, and A. Hatzakis. 2001. Comparative evaluation of the QUANTIPLEX HIV-1 RNA 2.0 and 3.0 (bDNA) assays and the AMPLICOR HIV-1 MONITOR v1.5 test for the quantitation of human immunodeficiency virus type 1 RNA in plasma. J. Virol. Methods 91:67-74.
2. Boyer, J. L., E. B. Chang, D. E. Collyar, L. D. DeLeve, J. Feinberg, T. A. Judge, F. M. Muggia, C. L. Shapiro, S. A. Spector, F. J. Suchy, P. L. Tomsko, and B. J. Turner. 2002. National Institutes of Health Consensus Development Conference statement: management of hepatitis C. [Online.] http: //consensus@nih.gov/cons/116/091202116cdc_statement.htm.
3. Bushnell, S., J. Budde, T. Catino, J. Cole, A. Derti, R. Kelso, M. L. Collins, G. Molino, P. Sheridan, J. Monahan, and M. Urdea. 1999. ProbeDesigner: for the design of probesets for branched DNA (bDNA) signal amplification assays. Bioinformatics 15:348-355.
4. Collins, M. L., B. Irvine, D. Tyner, E. Fine, C. Zayati, C. Chang, T. Horn, D. Ahle, J. Detmer, L. P. Shen, J. Kolberg, S. Bushnell, M. S. Urdea, and D. D. Ho. 1997. A branched DNA signal amplification assay for quantification of nucleic acid targets below 100 molecules/ml. Nucleic. Acids Res. 25:2979-2984.
5. Elbeik. T., R. Delassandro, Y. M. A. Chen, S. V. Soutchkov, R. A. Loftus, and S. Beringer. 2003. Global cost modeling analysis of HIV-1 and HCV viral load assays: a comparative cost analysis of Bayer VERSANT® assay, Roche AMPLICOR MONITOR® test and COBAS AMPLCOR MONITOR® test. Expert Rev. Pharmacoeconomics Outcomes Res. 3:383-407.
6. Elbeik, T., W. G. Alvord, R. Trichavaroj, M. de Souza, R. Dewar, A. Brown, D. Chernoff, N. L. Michael, P. Nassos, K. Hadley, and V. L. Ng. 2002. Comparative analysis of HIV-1 viral load assays on subtype quantification: Bayer VERSANT HIV-1 RNA 3.0 versus Roche Amplicor HIV-1 Monitor version 1.5. J. Acquir. Immune Defic. Syndr. 29:330-339.
7. Elbeik, T., R. A. Loftus, and S. Beringer. 2002. Health care industries' perspective of viral load assays: the VERSANT HIV-1 RNA 3.0 assay. Expert Rev. Mol. Diagn. 2:275-285.
8. Fauchi, A. S., J. G. Bartlett, E. P. Goosby, and J. Kates. 2002. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. [Online.] http://aidsinfo.nih.gov/guidelines/adult/AAMay23.pdf.
9. Fleiss, J. L. 1981. Statistical methods for rates and proportions. John Wiley & Sons, Inc., New York, N.Y.
10. Gleaves, C. A., J. Welle, M. Campbell, T. Elbeik, V. Ng, P. E. Taylor, K. Kuramoto, S. Aceituno, E. Lewalski, B. Joppa, L. Sawyer, C. Schaper, D. McNairn, and T. Quinn. 2002. Multicenter evaluation of the Bayer VERSANT HIV-1 RNA 3.0 assay: analytical and clinical performance. J. Clin. Virol. 25:205-216.
11. Hendricks, D. A., B. J. Stowe, B. S. Hoo, J. Kolberg, B. D. Irvine, P. D. Neuwald, M. S. Urdea, and R. P. Perrillo. 1995. Quantitation of HBV DNA in human serum using a branched DNA (bDNA) signal amplification assay. Am. J. Clin. Pathol. 104:537-546.
12. Kern, D., M. Collins, T. Fultz, J. Detmer, S. Hamren, J. J. Peterkin, P. Sheridan, M. Urdea, R. White, T. Yeghiazarian, and J. Todd. 1996. An enhanced-sensitivity branched-DNA assay for quantification of human immunodeficiency virus type 1 RNA in plasma. J. Clin. Microbiol. 34:3196-3202.
13. Ross, R. S., S. S. Viazov, Sarr, S. Hoffmann, A. Kramer, and M. Roggendorf. 2002. Quantitation of hepatitis C virus RNA by third generation branched DNA-based signal amplification assay. J. Virol. Methods 101:159-168.
14. Todd, J., C. Pachl, R. White, T. Yeghiazarian, P. Johnson, B. Taylor, M. Holodniy, D. Kern, S. Hamren, D. Chernoff, et al. 1995. Performance characteristics for the quantitation of plasma HIV-1 RNA using branched DNA signal amplification technology. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 10(Suppl. 2):S35-S44.